Download Files:
Products Details
Product Description
– PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity[1].
Web ID
– HY-146166
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C18H14N4O2
References
– [1]Vanderlan Nogueira Holanda, et al. Antileishmanial activity of 4-phenyl-1-[2-(phthalimido-2-yl)ethyl]-1H-1,2,3-triazole (PT4) derivative on <i>Leishmania amazonensis</i> and <i>Leishmania braziliensis</i>: In silico ADMET, in vitro activity, docking and m
CAS Number
– 1280738-47-7
Molecular Weight
– 318.33
SMILES
– O=C1N(CCN2N=NC(C3=CC=CC=C3)=C2)C(C4=C1C=CC=C4)=O
Clinical Information
– No Development Reported
Research Area
– Infection; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Parasite;Reactive Oxygen Species
Isoform
– Leishmania
Pathway
– Anti-infection;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
